Clinical Trials Logo

Progression clinical trials

View clinical trials related to Progression.

Filter by:

NCT ID: NCT04213664 Recruiting - Clinical trials for Renal Cell Carcinoma

Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.

LMR
Start date: December 31, 2019
Phase:
Study type: Observational

PubMed, ScienceDirect, Cochrane Database of Systematic Reviews will be used to search for articles published from January 1965 to July 2019 using the key words "renal cancer", "lymphocyte to monocyte ratio" and "prognosis". No restrictions to date, language, or article type will be applied. Cohort or observational studies in patients with non-metastatic renal cell carcinoma histopathologically confirmed, with hazard ratios (HR) and corresponding 95% confidence intervals (CI) that assessed association between LMR and overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and disease-free survival (DFS) will be analyzed.

NCT ID: NCT03582527 Recruiting - Survival Clinical Trials

PD-L1 Expression in Advanced Osteosarcoma

Start date: June 1, 2018
Phase:
Study type: Observational [Patient Registry]

The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.

NCT ID: NCT03509779 Recruiting - Surgery Clinical Trials

Pronostic and Predictive Value of EMT in Localized Lung Cancer

TWISTlung
Start date: October 20, 2014
Phase:
Study type: Observational [Patient Registry]

The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC. This study will potentially lead to specific treatment recommendations, thanks to an integrated molecular approach including DNA, RNA and miR profiling In vitro analyses using lung cancer cell lines will subsequently be conducted to validate markers identified in tumor screenings.

NCT ID: NCT03121768 Recruiting - Bladder Cancer Clinical Trials

A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: May 15, 2017
Phase: N/A
Study type: Observational

A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high risk groups and including all potential and highly prognostic factors.